Recent Advances in Peptide Drug Discovery: Novel Strategies and Targeted Protein Degradation DOI Creative Commons
Katarina Vrbnjak, Raj Nayan Sewduth

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(11), P. 1486 - 1486

Published: Nov. 20, 2024

Recent technological advancements, including computer-assisted drug discovery, gene-editing techniques, and high-throughput screening approaches, have greatly expanded the palette of methods for discovery peptides available to researchers. These emerging strategies, driven by recent advances in bioinformatics multi-omics, significantly improved efficiency peptide when compared with traditional vitro vivo methods, cutting costs improving their reliability. An added benefit peptide-based drugs is ability precisely target protein-protein interactions, which are normally a particularly challenging aspect discovery. Another breakthrough this field targeted protein degradation through proteolysis-targeting chimeras. revolutionary compounds represent noteworthy advancement over small-molecule inhibitors due unique mechanism action, allows specific proteins unprecedented specificity. The inclusion as protein-of-interest-targeting moiety versatility possibility targeting otherwise undruggable proteins. In review, we discuss various novel wet-lab computational multi-omic provide an overview therapeutic agents discovered these cutting-edge potential delivery drugs.

Language: Английский

Prostate cancer epigenetics — from pathophysiology to clinical application DOI
Vera Constâncio, João Lobo, José Pedro Sequeira

et al.

Nature Reviews Urology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 16, 2025

Language: Английский

Citations

2
Unleashing the power of peptides in prostate cancer immunotherapy: mechanism, facts and perspectives DOI Creative Commons

Xiaoya Li,

Fang Yang, Meijing Wang

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 26, 2025

Prostate cancer, the second most common cancer in men, often progresses to castration-resistant prostate despite androgen deprivation therapy. Immunotherapy, revolutionary treatment, has limited efficacy due its "cold tumor" nature. Peptides, with unique advantages, offer new hope. This review explores how peptide-based tumor immunotherapy can transform from a "cold" "hot" state. It modulates immunosuppressive microenvironment by regulating non-immune cells (such as cancer-associated fibroblasts, endothelial cells, and adipose stromal cells), repolarizing tumor-associated macrophages, activating NK tuning cytokines. Additionally, peptides induce immunogenic cell death (ICD) through ferroptosis, pyroptosis, autophagy modulation. The also revisits existing immunotherapies, including immune checkpoint blockade, CAR T therapy, dendritic vaccines, highlighting enhance their effectiveness safety. Finally, two strategies development stage, peptide-integrated Proteolysis-Targeting Chimera therapy peptide-involved epigenomic are introduced, showing great potential for future treatment.

Language: Английский

Citations

0
The Peptide PROTAC Modality: A New Strategy for Drug Discovery DOI Creative Commons
Youmin Zhu, Yu Dai,

Yun-Cai Tian

et al.

MedComm, Journal Year: 2025, Volume and Issue: 6(4)

Published: March 24, 2025

ABSTRACT In recent years, proteolysis targeting chimera (PROTAC) technology has made significant progress in the field of drug development. Traditional drugs mainly focus on inhibiting or activating specific proteins, while PROTAC provides new ideas for treating various diseases by inducing degradation target proteins. Especially peptide PROTACs, due to their unique structural and functional characteristics, they have become a hot research topic. This review detailed description key components, mechanisms, design principles elaborates applications skin‐related diseases, oncology, other potential therapeutic fields, analyzes advantages challenges, looks forward future development prospects. The not only opens up paths development, but also solving resistance safety issues faced traditional small‐molecule drugs. Compared with PROTACs such as multitargeting, biodegradability, low toxicity, flexibility design. With deepening continuous maturity technology, are expected one important strategies discovery, providing hope treatment more intractable diseases. Peptide ushering era precision medicine.

Language: Английский

Citations

0
Advancements in delivery Systems for Proteolysis-Targeting Chimeras (PROTACs): Overcoming challenges and expanding biomedical applications DOI

Yawei Yu,

Weitong Hu,

Yihua Xu

et al.

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: unknown, P. 113719 - 113719

Published: April 1, 2025

Language: Английский

Citations

0
AI for drug discovery DOI

Louise Lloyd

Nature Reviews Urology, Journal Year: 2024, Volume and Issue: 21(9), P. 517 - 517

Published: Aug. 9, 2024

Citations

1
Selective p300 degradation via peptide PROTAC: a new therapeutic strategy for advanced prostate cancers DOI Creative Commons
Ling‐Yu Wang

EBioMedicine, Journal Year: 2024, Volume and Issue: 106, P. 105245 - 105245

Published: July 8, 2024

Language: Английский

Citations

0
Recent Advances in Peptide Drug Discovery: Novel Strategies and Targeted Protein Degradation DOI Creative Commons
Katarina Vrbnjak, Raj Nayan Sewduth

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(11), P. 1486 - 1486

Published: Nov. 20, 2024

Recent technological advancements, including computer-assisted drug discovery, gene-editing techniques, and high-throughput screening approaches, have greatly expanded the palette of methods for discovery peptides available to researchers. These emerging strategies, driven by recent advances in bioinformatics multi-omics, significantly improved efficiency peptide when compared with traditional vitro vivo methods, cutting costs improving their reliability. An added benefit peptide-based drugs is ability precisely target protein-protein interactions, which are normally a particularly challenging aspect discovery. Another breakthrough this field targeted protein degradation through proteolysis-targeting chimeras. revolutionary compounds represent noteworthy advancement over small-molecule inhibitors due unique mechanism action, allows specific proteins unprecedented specificity. The inclusion as protein-of-interest-targeting moiety versatility possibility targeting otherwise undruggable proteins. In review, we discuss various novel wet-lab computational multi-omic provide an overview therapeutic agents discovered these cutting-edge potential delivery drugs.

Language: Английский

Citations

0